Number II - Pemphigus vulgaris

被引:43
作者
Black, M
Mignogna, MD
Scully, C
机构
[1] UCL, Eastman Dent Inst, London WC1X 8LD, England
[2] Kings Coll London, Guys & St Thomas Hosp, Sch Med, London WC2R 2LS, England
[3] Univ Naples Federico II, Naples, Italy
关键词
pernphigus; autoimmune; immunosuppressants; oral; vesiculobullous; skin;
D O I
10.1111/j.1601-0825.2005.01139.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Pemphigus is a group of potentially life-threatening autoimmune diseases characterized by cutaneous and/or mucosal blistering. Pemphigus vulgaris (PV), the most common variant, is characterized by circulating IgG antibodies directed against desmoglein 3 (Dsg3), with about half the patients also having DsgI autoantibodies. There is a fairly strong genetic background to pemphigus with linkage to HLA class II alleles and ethnic groups such as Ashkenazi Jews and those of Mediterranean and Indian origin, are especially liable. Oral lesions are initially vesiculobullous but readily rupture, new bullae developing as the older ones rupture and ulcerate. Biopsy of perilesional tissue, with histological and immunostaining examination are essential to the diagnosis. Serum autoantibodies to either DsgI or Dsg3 are best detected using both normal human skin and monkey oesophagus or by enzyme-linked immunosorbent assay. Before the introduction of corticosteroids, PV was typically fatal mainly from dehydration or secondary systemic infections. Current treatment is largely based on systemic immunosuppression using corticosteroids, with azathioprine or other adjuvants or alternatives but newer therapies with potentially fewer adverse effects, also appear promising.
引用
收藏
页码:119 / 130
页数:12
相关论文
共 190 条
[71]   Heterogeneous MHC II restriction pattern of autoreactive desmoglein 3 specific T cell responses in pemphigus vulgaris patients and normals [J].
Hertl, M ;
Karr, RW ;
Amagai, M ;
Katz, SI .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) :388-392
[72]   Recognition of desmoglein 3 by autoreactive T cells in pemphigus vulgaris patients and normals [J].
Hertl, M ;
Amagai, M ;
Sundaram, H ;
Stanley, J ;
Ishii, K ;
Katz, SI .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (01) :62-66
[73]  
Hertl Michael, 1999, Journal of Dermatology (Tokyo), V26, P748
[74]   Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins [J].
Herzog, S ;
Schmidt, E ;
Goebeler, M ;
Bröcker, EB ;
Zillikens, D .
ACTA DERMATO-VENEREOLOGICA, 2004, 84 (01) :48-52
[75]   Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus [J].
Ioannides, D ;
Chrysomallis, F ;
Bystryn, JC .
ARCHIVES OF DERMATOLOGY, 2000, 136 (07) :868-872
[76]   Development of pemphigus vulgaris in a patient with pemphigus foliaceus: Antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay [J].
Ishii, K ;
Amagai, M ;
Ohata, Y ;
Shimizu, H ;
Hashimoto, T ;
Ohya, K ;
Nishikawa, T .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (05) :859-861
[77]   Detection of human herpesvirus 8 DNA in pemphigus and chronic blistering skin diseases [J].
Jang, HS ;
Oh, CK ;
Lim, JY ;
Jun, ES ;
Kim, YS ;
Kwon, KS .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2000, 15 (04) :442-448
[78]   Pemphigus vulgaris: the other half of the story [J].
Kalish, RS .
JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (12) :1433-1435
[79]   ORAL PEMPHIGUS-VULGARIS [J].
KANWAR, AJ ;
DHAR, S .
PEDIATRIC DERMATOLOGY, 1995, 12 (02) :195-197
[80]   Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations [J].
Kaplan, I ;
Hodak, E ;
Ackerman, L ;
Mimouni, D ;
Anhalt, GJ ;
Calderon, S .
ORAL ONCOLOGY, 2004, 40 (06) :553-562